MediWound Ltd. (MDWD) Stock Price
MDWDStock
$11.85−39.14%52W
Market Cap$152.99M
P/E—
PEG Ratio—
Div yield—
Beta0.02
MDWD Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-42.96%
Price vs S&P 500 (4W)-9.64%
VGM Score34.18
MDWD Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.77 | -$0.57 | +25.97%(+$0.20) | |
| Q1 2026 | -$0.66 | -$0.23 | +65.26%(+$0.43) | |
| Q4 2025 | -$0.61 | -$0.56 | +8.50%(+$0.05) | |
| Q3 2025 | -$0.83 | -$0.24 | +71.01%(+$0.59) | |
| Q2 2025 | -$0.57 | -$1.23 | -116.55%(-$0.66) |
MDWD Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.17
4.17
4.17
4.17
Industry Peers — Pharmaceutical Preparations(21)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
MDWDMediWound Ltd. | D | F | C | 12.9x | -40.3% | 15.5% | — | $11.85 |
| RGCRegencell Bioscience Holdings Limited Ordinary Shares | — | — | B | — | — | — | — | $9.59 |
| DFTXDefinium Therapeutics, Inc. Common Shares | — | — | B | — | — | — | — | $32.10 |
| TRLVTrulieve Cannabis Corp. | B | C | A | 1.7x | -3.9% | 59.5% | — | $10.01 |
| CRONCronos Group Inc. Common Share | C | B | A | 6.6x | 37.5% | 46.5% | -50.0% | $3.21 |
| TLRYTilray Brands, Inc. Common Stock | B | B | D | 0.5x | 15.9% | 29.1% | — | $3.04 |
| CGCCanopy Growth Corporation Common Shares | B | C | D | 1.6x | 6.8% | 28.5% | — | $0.71 |
| SNDLSundial Growers Inc. Common Shares | B | C | B | 0.5x | -1.7% | 26.2% | — | $1.25 |
| GLASGlass House Brands Inc. | B | C | D | 1.2x | -25.6% | 30.8% | — | $3.19 |
| USNAUSANA Health Sciences Inc | B | D | C | 0.3x | 5.7% | 77.5% | -37.0% | $15.54 |
| ACBAurora Cannabis Inc. Common Shares | B | D | B | 1.3x | -18.9% | 6.3% | — | $3.99 |
About MediWound Ltd.
MediWound Ltd is a biopharmaceutical company developing treatments for severe burns and hard-to-heal wounds. Its lead product, NexoBrid, is FDA-approved for eschar removal in severe burns and offers a non-surgical alternative to conventional debridement. The company is advancing a pipeline including EscharEx for chronic wound debridement and MW005 for non-melanoma skin cancer, with revenue primarily generated in the United States.